Omnicell (NASDAQ:OMCL) Issues Q1 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its first quarter 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.150-0.250 for the period, compared to the consensus earnings per share estimate of 0.210. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $260.2 million. Omnicell also updated its FY 2025 guidance to 1.650-1.850 EPS.

Wall Street Analyst Weigh In

OMCL has been the topic of a number of recent research reports. JPMorgan Chase & Co. lowered their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a report on Monday. Bank of America cut their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Benchmark reissued a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Finally, Wells Fargo & Company dropped their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $51.00.

Omnicell Stock Performance

Shares of OMCL stock opened at $35.35 on Friday. The company has a market cap of $1.65 billion, a P/E ratio of 130.93, a PEG ratio of 7.53 and a beta of 0.85. The firm has a fifty day moving average price of $39.16 and a 200 day moving average price of $42.64. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.75.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Sell-side analysts predict that Omnicell will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.